

# Paul G Richardson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5949616/publications.pdf>

Version: 2024-02-01

883  
papers

89,559  
citations

255

142  
h-index

407

277  
g-index

889  
all docs

889  
docs citations

889  
times ranked

45435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2022, 57, 95-105.	1.0	43
2	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
3	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2022, 36, 138-154.	3.3	28
4	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
5	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	1.2	7
6	Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. <i>Blood Advances</i> , 2022, 6, 181-188.	2.5	15
7	Sinusoidal Obstruction Syndrome/Hepatic Veno-Occlusive Disease. , 2022, , 143-163.		0
8	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1078-1087.	3.3	13
9	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 19-26.	0.8	5
10	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
11	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.2	13
12	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	2.2	32
13	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	2.0	3
14	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 416-427.	5.1	54
15	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2
16	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. <i>Cancer</i> , 2022, 128, 1996-2004.	2.0	12
17	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
18	Defibrotide Therapy for SARS-CoV-2 ARDS. <i>Chest</i> , 2022, 162, 346-355.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Efficacy and tolerability of <sc>onceâ€week</sc> selinexor, bortezomib, and dexamethasone in comparison with standard <sc>twiceâ€week</sc> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <sc>BOSTON</sc> study. American Journal of Hematology, 2022, 97, .	2.0	7
20	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	2.8	5
21	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	13.9	173
22	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	1.3	3
23	Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. Leukemia and Lymphoma, 2022, 63, 2403-2412.	0.6	2
24	Lenalidomide, bortezomib, and dexamethasone (RvD) Â± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. Journal of Clinical Oncology, 2022, 40, LBA4-LBA4.	0.8	3
25	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8012-8012.	0.8	2
26	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	2.8	16
27	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. British Journal of Haematology, 2022, 199, 190-204.	1.2	9
28	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2021, 106, 1182-1187.	1.7	27
29	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. American Journal of Hematology, 2021, 96, E5-E8.	2.0	20
30	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 88.e1-88.e6.	0.6	4
31	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	5.1	46
32	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 757-767.	0.8	98
33	Overall survival with oral selinexor plus lowâ€dose dexamethasone versus realâ€world therapy in tripleâ€classâ€refractory multiple myeloma. EJHaem, 2021, 2, 48-55.	0.4	8
34	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 2021, 35, 1722-1731.	3.3	35
35	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: longâ€term survival followâ€up from the Phase II study Oâ€12â€M1. British Journal of Haematology, 2021, 193, 1105-1109.	1.2	11
36	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematology,the, 2021, 8, e45-e54.	2.2	79

#	ARTICLE	IF	CITATIONS
37	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. <i>Cell Reports</i> , 2021, 34, 108532.	2.9	54
38	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	2.8	11
39	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 23.	2.8	31
40	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	1.2	49
41	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	1.2	16
42	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
43	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation – a case series. <i>British Journal of Haematology</i> , 2021, 193, e36-e38.	1.2	1
44	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
45	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
46	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. <i>British Journal of Haematology</i> , 2021, 193, 213-215.	1.2	0
47	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 55.	2.8	4
48	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	6.9	11
49	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	2.6	64
50	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021, 104, 106576.	0.4	19
51	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) – Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8037-8037.	0.8	4
52	Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply. <i>Lancet</i> , The, 2021, 397, 1621-1623.	6.3	1
53	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8048-8048.	0.8	1
54	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12082-12082.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	3.3	13
56	Effect of age and frailty on the efficacy and tolerability of once-a-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	2.0	16
57	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
58	ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. <i>Science Advances</i> , 2021, 7, .	4.7	11
59	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	1.1	23
60	Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. <i>EJHaem</i> , 2021, 2, 680-681.	0.4	3
61	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.2	10
62	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	1.5	6
63	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	1.0	6
64	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	2.0	15
65	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	0.8	53
66	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	3.2	18
67	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	1.1	6
68	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	2.0	15
69	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	2.0	10
70	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
71	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27
72	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	3.3	43
74	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 169.	2.8	2
75	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021, 23, 1199-1211.	4.6	22
76	Reply to G. R. Mohyuddin et al and A. Garfall et al. <i>Journal of Clinical Oncology</i> , 2021, , JCO2102081.	0.8	0
77	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 3801-3801.	0.6	1
78	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021, 138, 2852-2852.	0.6	7
79	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , 2021, 138, 2731-2731.	0.6	18
80	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	0.6	20
81	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , 2021, 138, 2733-2733.	0.6	1
82	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. <i>Blood</i> , 2021, 138, 2732-2732.	0.6	0
83	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	0.6	9
84	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis. <i>Blood</i> , 2021, 138, 4780-4780.	0.6	0
85	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. <i>Blood</i> , 2021, 138, 4779-4779.	0.6	0
86	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , 2021, 138, 4969-4969.	0.6	0
87	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1613-1613.	0.6	3
88	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	0.6	6
89	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
90	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 8-17.e16.	0.2	74

#	ARTICLE	IF	CITATIONS
91	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 344-353.	3.2	66
92	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539.	2.0	14
93	Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile. <i>British Journal of Haematology</i> , 2020, 188, 483-485.	1.2	4
94	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	2.2	56
95	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , 2020, 21, 207-221.	5.1	544
96	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	0.8	45
97	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	1.9	28
98	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	0.6	56
99	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 106.	2.8	40
100	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1395-1404.	1.4	22
101	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.2	5
102	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 1317-1330.	5.1	155
103	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	1.9	17
104	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , 2020, 396, 1563-1573.	6.3	188
105	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
106	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
107	The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
108	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	1.0	34
110	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 583-587.	1.2	9
111	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. <i>Blood Cancer Journal</i> , 2020, 10, 29.	2.8	6
112	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 1448-1453.	1.2	58
113	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1342-1349.	2.0	19
114	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1&sup2; study. <i>Lancet Haematology</i> , 2020, 7, e395-e407.	2.2	65
115	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020, 9, 378.	1.8	16
116	Selinexor for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 399-408.	0.9	46
117	Clinical benefit of ixazomib plus lenalidomide&dashdash;dexamethasone in myeloma patients with non&dashdash;canonical NF&dashdash;B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	1.1	7
118	Randomized, placebo&dashdash;controlled, phase 3 study of perfosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	0.4	8
119	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 351-357.	0.2	23
120	Health-related quality-of-life results from the phase 3 OPTIMISM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	0.6	11
121	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	2.2	74
122	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020, 136, 39-39.	0.6	70
123	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. <i>Blood</i> , 2020, 136, 41-43.	0.6	3
124	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
125	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , 2020, 136, 44-46.	0.6	2
126	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	0.6	19



#	ARTICLE	IF	CITATIONS
127	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. Blood, 2020, 136, 15-17.	0.6	6
128	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 16-17.	0.6	28
129	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. Blood, 2020, 136, 4-5.	0.6	11
130	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. Blood, 2020, 136, 7-8.	0.6	4
131	A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action. Blood, 2020, 136, 34-34.	0.6	1
132	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	0.8	110
133	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8500-8500.	0.8	40
134	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. Journal of Clinical Oncology, 2020, 38, 8519-8519.	0.8	13
135	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. Journal of Clinical Oncology, 2020, 38, e20570-e20570.	0.8	5
136	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3120.	1.0	35
137	Pomalidomide, bortezomib, and dexamethasone (PvD) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISM.. Journal of Clinical Oncology, 2020, 38, e20562-e20562.	0.8	2
138	Melflufen- A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma. Oncology & Hematology Review, 2020, 16, 12.	0.2	1
139	Pomalidomide+bortezomib+dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISM. Cancer Science, 2020, 111, 2116-2122.	1.7	4
140	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	0.6	1
141	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. Blood, 2020, 136, 2-4.	0.6	4
142	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. Blood, 2020, 136, 31-31.	0.6	0
143	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. Blood, 2020, 136, 20-22.	0.6	0
144	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. Blood, 2020, 136, 27-29.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Variation in the Treatment of Multiple Myeloma in the Real World. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
146	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020, 136, 25-26.	0.6	1
147	Current antibody-based therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18, 736-748.	0.3	0
148	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
149	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
150	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019, 33, 426-438.	3.3	59
151	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
152	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	6.3	435
153	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e353-e354.	0.2	7
154	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	2.0	42
155	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 337-347.	0.5	4
156	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45
157	Towards a better understanding of monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2019, 186, 653-654.	1.2	0
158	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 781-794.	5.1	254
159	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , 2019, 134, 123-133.	0.6	82
160	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	2.8	38
161	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , 2019, 33, 2208-2226.	3.3	27
162	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	1.2	12

#	ARTICLE	IF	CITATIONS
163	ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	1.1	11
164	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). <i>Bone Marrow Transplantation</i> , 2019, 54, 1951-1962.	1.3	57
165	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e352-e353.	0.2	2
166	Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e283.	0.2	3
167	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e33.	0.2	7
168	ICARIA-MM study: efficacy analysis according to prior lines of treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e245-e246.	0.2	5
169	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019, 10, 486-489.	0.5	24
170	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	0.9	7
171	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 478-486.	3.2	29
172	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	1.2	18
173	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019, 134, 691-691.	0.6	37
174	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	0.6	12
175	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , 2019, 134, 1883-1883.	0.6	8
176	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. <i>Blood</i> , 2019, 134, 1839-1839.	0.6	1
177	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3169-3169.	0.6	6
178	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	0.6	10
179	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	0.6	13
180	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1857-1857.	0.6	8

#	ARTICLE	IF	CITATIONS
181	A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2019, 37, 8004-8004.	0.8	15
182	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. Journal of Clinical Oncology, 2019, 37, 8014-8014.	0.8	8
183	Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2019, 37, 8043-8043.	0.8	0
184	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. Blood, 2019, 134, 3487-3487.	0.6	3
185	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. Blood, 2019, 134, 318-318.	0.6	0
186	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. Hematologic Malignancies, 2018, , 73-96.	0.2	1
187	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830.	1.2	32
188	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 942-945.	1.3	27
189	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncology, 2018, 14, 1035-1047.	1.1	65
190	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 113-124.	1.3	27
191	Current use of monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology, 2018, 181, 447-459.	1.2	37
192	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 2018, 32, 1838-1841.	3.3	42
193	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia, 2018, 32, 2032-2036.	3.3	12
194	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology, 2018, 180, 271-275.	1.2	24
195	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clinical Pharmacokinetics, 2018, 57, 529-538.	1.6	24
196	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NCT00524107): final study results. British Journal of Haematology, 2018, 180, 41-51.	1.2	62
197	CD38 antibodies in multiple myeloma: back to the future. Blood, 2018, 131, 13-29.	0.6	329
198	The use of defibrotide in blood and marrow transplantation. Blood Advances, 2018, 2, 1495-1509.	2.5	54

#	ARTICLE	IF	CITATIONS
199	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	2.8	170
200	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	1.3	33
201	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , 2018, 19, 1641-1653.	5.1	193
202	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42
203	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	13.9	413
204	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	0.6	301
205	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT2 trial. <i>Cancer</i> , 2018, 124, 4032-4043.	2.0	118
206	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.2	6
207	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. <i>British Journal of Haematology</i> , 2018, 181, 628-636.	1.2	20
208	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	1.2	30
209	Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	1.2	95
210	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	0.6	38
211	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	1.2	30
212	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	1.1	10
213	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.5	63
214	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 222-230.	1.2	118
215	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
216	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 433-446.	1.2	33

#	ARTICLE	IF	CITATIONS
217	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, e183267.	3.4	63
218	Defibrotide for the treatment of hepatic venoocclusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27269.	0.8	25
219	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018, 132, 1960-1960.	0.6	1
220	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018, 132, 1967-1967.	0.6	2
221	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq1 1 0.7843 14rgBT /Overlock 10	0.6	1
222	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
223	OP-106 Horizon " Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018, 132, 600-600.	0.6	12
224	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	0.6	17
225	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 804-804.	0.6	42
226	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (Pvd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISM trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8001-8001.	0.8	15
227	Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8038-8038.	0.8	4
228	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. <i>Blood</i> , 2018, 132, 3234-3234.	0.6	0
229	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 3263-3263.	0.6	1
230	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation " Results from the Tourmaline-MM1 Study. <i>Blood</i> , 2018, 132, 473-473.	0.6	0
231	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018, 132, 1981-1981.	0.6	1
232	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018, 132, 1367-1367.	0.6	0
233	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	3.2	203
234	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	1.0	24

#	ARTICLE	IF	CITATIONS
235	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017, 129, 1308-1319.	0.6	36
236	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
237	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
238	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 112-118.	1.2	72
239	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
240	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 756-763.	1.2	21
241	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
242	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
243	Marizomib for central nervous system multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 221-225.	1.2	49
244	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	5.1	394
245	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
246	Twice-weekly ixazomib plus lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S337.	0.2	1
247	ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
248	Realgar nanoparticles versus arsenic compounds induce <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 756-771.	1.2	26
249	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , 2017, 12, 643-654.	1.7	19
250	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 885-898.	1.4	25
251	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e431-e442.	2.2	132
252	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29

#	ARTICLE	IF	CITATIONS
253	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. <i>International Journal of Dermatology</i> , 2017, 56, 1058-1060.	0.5	2
254	Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S335-S336.	0.2	1
255	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , 2017, 10, 933-939.	1.0	11
256	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sup>E</sup> follow-up and <sup>post-hoc</sup> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
257	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1817-1825.	2.0	27
258	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <sup>vs</sup> placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	1.7	48
259	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 561-584.	2.7	229
260	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	0.9	10
261	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
262	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
263	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <sup>PANORAMA</sup> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	1.2	16
264	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	3.1	25
265	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies. <i>JAMA Oncology</i> , 2017, 3, 980.	3.4	77
266	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 75-93.	0.7	24
267	New developments in the management of relapsed/refractory multiple myeloma &ndash; the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 107-121.	0.7	19
268	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	6.9	56
269	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
270	Prospective Evaluation of Magnetic Resonance Imaging and [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	0.8	247



#	ARTICLE	IF	CITATIONS
271	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017, 8, 66641-66655.	0.8	65
272	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , 2017, 130, 741-741.	0.6	33
273	CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma. Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8037-8037.	0.8	1
274	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	0.6	4
275	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , 2016, 7, 77326-77341.	0.8	45
276	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
277	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
278	<sc>TAK</sc> 228 (formerly <sc>MLN</sc>0128), an investigational oral dual <sc>TORC</sc> 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 400-405.	2.0	89
279	C-terminal telopeptide of type 1 collagen in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 82-88.	1.2	10
280	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	0.6	98
281	Dual inhibition of oncogenic targets for B-cell malignancies. <i>Lancet Oncology</i> , The, 2016, 17, 547-549.	5.1	2
282	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1306-1312.	2.0	53
283	The Future of Myeloma Therapy: One Size Does Not Fit All. <i>Journal of Oncology Practice</i> , 2016, 12, 295-296.	2.5	2
284	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	13.9	861
285	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	0.6	89
286	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	0.6	179
287	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	0.6	255
288	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016, 127, 2693-2700.	0.6	66

#	ARTICLE	IF	CITATIONS
289	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	0.6	347
290	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	0.6	121
291	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5688-5695.	3.2	18
292	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 169-194.	0.2	6
293	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	13.9	1,210
294	Defibrotide for the Treatment of Hepatic Veneno-Occlusive Disease: Final Results From the International Compassionate-Use Program. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1874-1882.	2.0	78
295	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016, 174, 711-720.	1.2	44
296	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1291-1301.	1.4	10
297	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1569-1578.	5.1	164
298	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016, 127, 3225-3236.	0.6	244
299	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
300	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , the, 2016, 3, e506-e515.	2.2	121
301	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13162-13167.	3.3	112
302	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	0.6	27
303	A novel alkylating agent Melflufen induces irreversible <sc>DNA</sc> damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , 2016, 174, 397-409.	1.2	49
304	Multiple Myeloma in Pregnancyâ€”A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e39-e45.	0.2	12
305	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016, 22, 4206-4214.	3.2	28
306	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294

#	ARTICLE	IF	CITATIONS
307	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1551-1560.	6.3	724
308	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	5.8	87
309	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	1.3	24
310	Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 344-348.	2.0	4
311	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016, 128, 1148-1148.	0.6	23
312	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2122-2122.	0.6	1
313	Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2123-2123.	0.6	19
314	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	0.6	3
315	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , 2016, 128, 3326-3326.	0.6	6
316	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016, 128, 66-66.	0.6	3
317	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	0.6	38
318	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2016, 128, 976-976.	0.6	17
319	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8014-8014.	0.8	7
320	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	0.6	0
321	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 2134-2134.	0.6	0
322	Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. <i>Blood</i> , 2016, 128, 5689-5689.	0.6	0
323	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5815-5815.	0.6	0
324	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015, 55, 1545-1554.	0.8	204

#	ARTICLE	IF	CITATIONS
325	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, 100-106.	1.7	33
326	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
327	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , 2015, 126, 921-922.	0.6	71
328	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. <i>British Journal of Haematology</i> , 2015, 171, 798-812.	1.2	41
329	Combination of a Selective HSP90 Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015, 10, e0143847.	1.1	20
330	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
331	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	2.2	140
332	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1491-1501.	0.5	1
333	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.	2.0	58
334	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S110.	2.0	3
335	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 793-798.	2.0	23
336	Promising therapies in multiple myeloma. <i>Blood</i> , 2015, 126, 300-310.	0.6	86
337	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
338	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	1.1	48
339	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4607-4618.	3.2	271
340	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015, 5, 972-987.	7.7	97
341	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , 2015, 21, 2660-2662.	3.2	40
342	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. <i>British Journal of Haematology</i> , 2015, 170, 66-79.	1.2	16

#	ARTICLE	IF	CITATIONS
343	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	1.1	25
344	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide+bortezomib combinations. <i>British Journal of Haematology</i> , 2015, 169, 843-850.	1.2	66
345	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
346	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	13.9	948
347	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.	3.2	212
348	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 42-54.	12.5	175
349	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015, 126, 1827-1827.	0.6	10
350	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015, 126, 23-23.	0.6	37
351	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.	0.6	22
352	A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism. <i>Blood</i> , 2015, 126, 3000-3000.	0.6	1
353	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015, 126, 3029-3029.	0.6	1
354	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015, 126, 3031-3031.	0.6	3
355	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	0.6	12
356	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , 2015, 126, 3040-3040.	0.6	18
357	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). <i>Blood</i> , 2015, 126, 3055-3055.	0.6	5
358	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015, 126, 375-375.	0.6	19
359	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015, 126, 391-391.	0.6	99
360	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	0.6	20

#	ARTICLE	IF	CITATIONS
361	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4217-4217.	0.6	8
362	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4220-4220.	0.6	7
363	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) <a href="http://www.bloodjournal.org">http://www.bloodjournal.org</a> / DOI: 10.1182/blood-2015-07-4741	0.6	1
364	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015, 126, 4246-4246.	0.6	2
365	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4256-4256.	0.6	4
366	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). <i>Blood</i> , 2015, 126, 507-507.	0.6	30
367	Defibrotide for the Treatment of Hepatic Veneno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	0.6	1
368	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1. <i>Journal of Clinical Oncology</i> , 2015, 33, 8526-8526.	0.8	5
369	Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. <i>Blood</i> , 2015, 126, 4253-4253.	0.6	0
370	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. <i>Blood</i> , 2015, 126, 5322-5322.	0.6	0
371	Targeting Replicative Stress to Treat Hematological Disorders. <i>Blood</i> , 2015, 126, 2419-2419.	0.6	0
372	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 599-609.	0.3	26
373	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , 2014, 123, 706-716.	0.6	254
374	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.4	63
375	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. <i>Journal of Clinical Oncology</i> , 2014, 32, 2125-2132.	0.8	22
376	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014, 124, 1038-1046.	0.6	192
377	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	0.9	25
378	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , 2014, 15, 1503-1512.	5.1	233

#	ARTICLE	IF	CITATIONS
379	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. <i>British Journal of Haematology</i> , 2014, 166, 401-409.	1.2	35
380	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3955-3961.	3.2	33
381	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 97-111.	1.0	65
382	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	0.6	174
383	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
384	The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. <i>Expert Review of Hematology</i> , 2014, 7, 1-3.	1.0	6
385	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
386	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	15.2	250
387	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
388	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
389	Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 127-131.	1.2	24
390	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
391	Novel Targeted Agents in the Treatment of Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 903-925.	0.9	15
392	Daratumumab granted breakthrough drug status. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 445-452.	1.9	45
393	Allogeneic Transplantation in Multiple Myeloma: A Potential Renaissance in the Era of Novel Therapies?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1078-1079.	2.0	1
394	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
395	The challenge of cross-trial comparisons using limited data. <i>Haematologica</i> , 2014, 99, e145-e146.	1.7	6
396	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.	0.6	98

#	ARTICLE	IF	CITATIONS
397	Novel anti- $\mu$ B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014, 123, 3128-3138.	0.6	361
398	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
399	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	0.6	54
400	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42
401	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1089-1108.	0.5	1
402	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. <i>Pediatric Oncology</i> , 2014, , 77-102.	0.5	1
403	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	0.9	16
404	Defibrotide for the Treatment of Hepatic Venous Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. <i>Blood</i> , 2014, 124, 1138-1138.	0.6	1
405	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014, 124, 2036-2036.	0.6	1
406	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 2120-2120.	0.6	4
407	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014, 124, 3081-3081.	0.6	16
408	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	0.6	11
409	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , 2014, 124, 3453-3453.	0.6	16
410	Phase 1b Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3483-3483.	0.6	14
411	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	0.6	12
412	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4772-4772.	0.6	7
413	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	0.6	25
414	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	0.6	18



#	ARTICLE	IF	CITATIONS
415	Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8588-8588.	0.8	4
416	SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. Blood, 2014, 124, 3441-3441.	0.6	26
417	Mimicking Myeloma Niche Ex Vivo. Blood, 2014, 124, 2076-2076.	0.6	0
418	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	0.6	0
419	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. Blood, 2014, 124, 27-27.	0.6	2
420	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venous Occlusive Disease. Blood, 2014, 124, 2470-2470.	0.6	0
421	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	0.6	0
422	Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 370-376.	0.2	41
423	Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes. Oral Oncology, 2013, 49, 977-983.	0.8	50
424	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemotherapy and Pharmacology, 2013, 71, 1357-1368.	1.1	62
425	Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 592-601.	0.8	5
426	Clinical Translation in Multiple Myeloma: From Bench to Bedside. Seminars in Oncology, 2013, 40, 549-553.	0.8	9
427	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research, 2013, 37, 829-837.	0.4	48
428	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, 1731-1740.	1.4	32
429	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood, 2013, 121, 2975-2987.	0.6	335
430	Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. Critical Reviews in Oncology/Hematology, 2013, 88, S36-S44.	2.0	30
431	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. British Journal of Haematology, 2013, 160, 351-358.	1.2	19
432	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 2013, 19, 734-744.	0.9	38

#	ARTICLE	IF	CITATIONS
433	<i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 3019-3031.	3.2	86
434	Kidney Disease and Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2007-2017.	2.2	125
435	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455.	0.8	250
436	Drug safety evaluation of defibrotide. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 123-136.	1.0	72
437	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013, 121, 1961-1967.	0.6	152
438	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	0.8	123
439	Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. <i>Blood</i> , 2013, 121, 858-858.	0.6	12
440	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , 2013, 122, 2331-2337.	0.6	281
441	Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013, 122, 1243-1255.	0.6	74
442	The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction. <i>Journal of Hematological Malignancies</i> , 2013, 3, .	0.0	0
443	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1869-1869.	0.6	2
444	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	0.6	12
445	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1970-1970.	0.6	4
446	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , 2013, 122, 1976-1976.	0.6	12
447	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013, 122, 4402-4402.	0.6	5
448	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013, 122, 535-535.	0.6	18
449	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 759-759.	0.6	19
450	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0

#	ARTICLE	IF	CITATIONS
451	Antitumor Activities Of An Oral Selective HSP90 $\alpha$ / $\beta$ Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4429-4429.	0.6	0
452	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). <i>Blood</i> , 2013, 122, 1854-1854.	0.6	0
453	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-44.	0.9	23
454	IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. <i>Oncology</i> , 2013, 27, 803-4, 806.	0.4	3
455	Dual Inhibition of Canonical and Noncanonical NF- $\kappa$ B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2012, 18, 4669-4681.	3.2	75
456	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	0.6	396
457	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 942-951.	1.9	49
458	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 253-265.	1.1	40
459	Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. <i>Blood</i> , 2012, 119, e131-e138.	0.6	29
460	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	0.6	178
461	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 2764-2767.	0.6	143
462	Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. <i>Blood</i> , 2012, 120, 3958-3967.	0.6	71
463	How I treat plasma cell leukemia. <i>Blood</i> , 2012, 120, 2376-2389.	0.6	115
464	Sequence analysis of $\beta$ -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. <i>Blood</i> , 2012, 120, 4513-4516.	0.6	69
465	Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.	1.2	26
466	Blockade of XBP1 splicing by inhibition of IRE1 $\alpha$ is a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012, 119, 5772-5781.	0.6	353
467	A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. <i>Cancer Cell</i> , 2012, 22, 345-358.	7.7	491
468	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 623-633.	1.5	90

#	ARTICLE	IF	CITATIONS
469	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , 2012, 5, 51-68.	1.0	30
470	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1960-1965.	0.8	184
471	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2012, 5, 291-302.	1.0	44
472	Latest advances and current challenges in the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 135-143.	12.5	193
473	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
474	New Proteasome Inhibitors in Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 258-266.	1.2	89
475	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	0.6	438
476	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012, 4, 253.	0.9	28
477	Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone. <i>Journal of Clinical Oncology</i> , 2012, 30, e175-e179.	0.8	10
478	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	13.9	1,024
479	Pathological crystallization of human immunoglobulins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13359-13361.	3.3	36
480	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*. <i>European Journal of Haematology</i> , 2012, 88, 1-7.	1.1	7
481	The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. <i>European Journal of Haematology</i> , 2012, 88, 446-449.	1.1	10
482	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. <i>British Journal of Haematology</i> , 2012, 158, 472-480.	1.2	55
483	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 1852-1852.	0.6	6
484	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	0.6	16
485	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 4039-4039.	0.6	3
486	Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study. <i>Blood</i> , 2012, 120, 4052-4052.	0.6	2

#	ARTICLE	IF	CITATIONS
487	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT). <i>Blood</i> , 2012, 120, 4053-4053.	0.6	4
488	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	0.6	1
489	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes. <i>Blood</i> , 2012, 120, 4072-4072.	0.6	5
490	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	0.6	11
491	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , 2012, 120, 73-73.	0.6	60
492	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2012, 19, 734-744.	0.9	1
493	Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3986-3986.	0.6	12
494	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012, 120, 565-565.	0.6	0
495	Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. <i>Blood</i> , 2012, 120, 1847-1847.	0.6	0
496	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1812-1812.	0.6	0
497	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. <i>Blood</i> , 2012, 120, 3995-3995.	0.6	0
498	<i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5311-5321.	3.2	290
499	Multiple Myeloma. <i>Annual Review of Medicine</i> , 2011, 62, 249-264.	5.0	121
500	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1916-1923.	0.8	78
501	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011, 4, 51-60.	1.0	23
502	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	13.5	2,432
503	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. <i>Lancet Oncology</i> , 2011, 12, 263-272.	5.1	88
504	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011, 117, 393-402.	0.6	199

#	ARTICLE	IF	CITATIONS
505	Management of Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1209-1216.	2.3	22
506	Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenetics and Genomics, 2011, 21, 121-129.	0.7	62
507	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood, 2011, 117, 4409-4419.	0.6	141
508	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
509	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	0.6	282
510	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood, 2011, 118, 535-543.	0.6	82
511	Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica, 2011, 96, 1662-1669.	1.7	56
512	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology, 2011, 152, 367-379.	1.2	118
513	Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. British Journal of Haematology, 2011, 152, 420-432.	1.2	23
514	Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. British Journal of Haematology, 2011, 153, 212-221.	1.2	13
515	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology, 2011, 153, 729-740.	1.2	102
516	Monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology, 2011, 154, 745-754.	1.2	68
517	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. British Journal of Haematology, 2011, 154, 755-762.	1.2	19
518	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 2011, 86, 23-31.	1.1	126
519	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics, 2011, 11, 1391-1402.	1.3	33
520	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. American Journal of Hematology, 2011, 86, 573-578.	2.0	21
521	Bortezomib and dexamethasone induction for multiple myeloma. Nature Reviews Clinical Oncology, 2011, 8, 8-10.	12.5	15
522	Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. Molecular Cancer Therapeutics, 2011, 10, 2034-2042.	1.9	246

#	ARTICLE	IF	CITATIONS
523	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. <i>Haematologica</i> , 2011, 96, 1170-1179.	1.7	72
524	Setting the standard for newly diagnosed multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 255-256.	12.5	2
525	Treatment Options for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1264-1277.	3.2	118
526	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2308-2315.	0.6	25
527	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4243-4249.	0.8	118
528	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management. , 2011, , 95-105.		1
529	Blockade of XBP1 Splicing by Inhibition of IRE1 $\hat{1}$ ± Is a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011, 118, 133-133.	0.6	2
530	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma “ Preliminary Safety Data. <i>Blood</i> , 2011, 118, 1873-1873.	0.6	2
531	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1874-1874.	0.6	1
532	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011, 118, 1881-1881.	0.6	11
533	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom’s Macroglobulinemia. <i>Blood</i> , 2011, 118, 2705-2705.	0.6	1
534	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011, 118, 2706-2706.	0.6	1
535	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2933-2933.	0.6	5
536	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 301-301.	0.6	9
537	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	0.6	28
538	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 303-303.	0.6	8
539	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide., <i>Blood</i> , 2011, 118, 3966-3966.	0.6	2
540	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study., <i>Blood</i> , 2011, 118, 3968-3968.	0.6	1

#	ARTICLE	IF	CITATIONS
541	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011, 118, 476-476.	0.6	16
542	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 479-479.	0.6	5
543	Defibrotide (DF) in the Treatment of Hepatic Venous Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2011, 118, 487-487.	0.6	3
544	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	0.6	9
545	Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics. , 2011, , 29-42.		0
546	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011, 118, 1409-1409.	0.6	0
547	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011, 118, 815-815.	0.6	0
548	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4134-4134.	0.6	0
549	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. <i>Blood</i> , 2011, 118, 1442-1442.	0.6	0
550	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. <i>Blood</i> , 2011, 118, 1377-1377.	0.6	0
551	A Novel Acanthoic Acid Analog NPI-1342 Blocks I $\kappa$ B Kinase- $\beta$ and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells. <i>Blood</i> , 2011, 118, 1841-1841.	0.6	0
552	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. <i>Blood</i> , 2011, 118, 3989-3989.	0.6	0
553	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011, 118, 1838-1838.	0.6	3
554	MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. <i>Oncology</i> , 2011, 25, 594, 596.	0.4	1
555	PI3K/p110 $\beta$ is a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2010, 116, 1460-1468.	0.6	177
556	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. <i>Blood</i> , 2010, 115, 5202-5213.	0.6	245
557	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010, 116, 1397-1404.	0.6	50
558	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	0.6	101



#	ARTICLE	IF	CITATIONS
559	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 4906-4915.	0.6	188
560	Improving the therapeutic index in myeloma. <i>Blood</i> , 2010, 116, 4733-4734.	0.6	4
561	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 115, 834-845.	0.6	104
562	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-4-S-12.	2.3	33
563	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010, 116, 3227-3237.	0.6	202
564	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	0.8	403
565	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010, 27, 1-6.	1.2	34
566	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2010, 149, 537-549.	1.2	119
567	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. <i>British Journal of Haematology</i> , 2010, 150, 428-437.	1.2	65
568	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. <i>British Journal of Haematology</i> , 2010, 150, 438-445.	1.2	62
569	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , 2010, 16, 483-489.	15.2	281
570	THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010009.	0.5	2
571	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	0.8	150
572	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 116, 679-686.	0.6	790
573	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.	3.2	62
574	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	1.7	40
575	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications—2. <i>Mayo Clinic Proceedings</i> , 2010, 85, 197-199.	1.4	5
576	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	0.8	358

#	ARTICLE	IF	CITATIONS
577	Hepatic Venous Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 157-168.	2.0	509
578	Defibrotide for the Treatment of Severe Hepatic Venous Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1005-1017.	2.0	227
579	Prediction of Venous Occlusive Disease Using Biomarkers of Endothelial Injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1180-1185.	2.0	85
580	A new standard of care in newly diagnosed multiple myeloma. <i>Lancet</i> , The, 2010, 376, 2043-2044.	6.3	0
581	Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. <i>Lancet Oncology</i> , The, 2010, 11, 1014-1016.	5.1	7
582	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1943-1943.	0.6	2
583	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. <i>Blood</i> , 2010, 116, 1951-1951.	0.6	17
584	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. <i>Blood</i> , 2010, 116, 3007-3007.	0.6	1
585	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2010, 116, 3013-3013.	0.6	12
586	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , 2010, 116, 3051-3051.	0.6	4
587	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Venous Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. <i>Blood</i> , 2010, 116, 3481-3481.	0.6	5
588	Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).. <i>Blood</i> , 2010, 116, 3482-3482.	0.6	3
589	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	0.6	2
590	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010, 116, 3952-3952.	0.6	9
591	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010, 116, 621-621.	0.6	14
592	Defibrotide (DF) In the Treatment of Severe Hepatic Venous Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2010, 116, 906-906.	0.6	3
593	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010, 116, 986-986.	0.6	6
594	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010, 116, 990-990.	0.6	5

#	ARTICLE	IF	CITATIONS
595	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010, 4, 215.	4.7	18
596	Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2010, 116, 618-618.	0.6	0
597	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010, 116, 2988-2988.	0.6	2
598	An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. <i>Blood</i> , 2010, 116, 2992-2992.	0.6	0
599	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. <i>Blood</i> , 2010, 116, 1838-1838.	0.6	0
600	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. <i>Blood</i> , 2010, 116, 456-456.	0.6	7
601	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010, 116, 1963-1963.	0.6	1
602	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor " Microenvironment Interactions.. <i>Blood</i> , 2010, 116, 1574-1574.	0.6	28
603	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. <i>Blood</i> , 2010, 116, 451-451.	0.6	0
604	Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. <i>Blood</i> , 2010, 116, 4064-4064.	0.6	0
605	Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. <i>Blood</i> , 2010, 116, 3023-3023.	0.6	9
606	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. <i>Blood</i> , 2010, 116, 5016-5016.	0.6	0
607	Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. <i>Oncology</i> , 2010, 24, 22-9.	0.4	10
608	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , 2009, Volume 1, 107-117.	0.9	8
609	Novel Therapies in the Treatment of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 947-960.	2.3	37
610	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 694-702.	0.6	31
611	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5713-5719.	0.8	155
612	Reply to C.A. Dasanu et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2294-2296.	0.8	3

#	ARTICLE	IF	CITATIONS
613	Use of defibrotide in the treatment and prevention of veno-occlusive disease. <i>Expert Review of Hematology</i> , 2009, 2, 365-376.	1.0	15
614	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. <i>Clinical Cancer Research</i> , 2009, 15, 7153-7160.	3.2	65
615	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 99-127.	1.0	48
616	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3518-3525.	0.8	241
617	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	0.8	154
618	Bortezomib induces canonical nuclear factor- $\kappa$ B activation in multiple myeloma cells. <i>Blood</i> , 2009, 114, 1046-1052.	0.6	329
619	Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. <i>Clinical Cancer Research</i> , 2009, 15, 1210-1221.	3.2	47
620	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 4028-4037.	3.2	200
621	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	7.7	242
622	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€”modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	1.2	289
623	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 164-170.	1.2	79
624	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	1.2	27
625	<i>In vitro</i> antiâ€”myeloma activity of the Aurora kinase inhibitor VEâ€”65. <i>British Journal of Haematology</i> , 2009, 147, 672-676.	1.2	26
626	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S40-S42.	1.4	0
627	Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. <i>Seminars in Hematology</i> , 2009, 46, 166-175.	1.8	54
628	Multiple myeloma. <i>Lancet</i> , The, 2009, 374, 324-339.	6.3	685
629	The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 627-634.	0.5	37
630	Biologic sequelae of $\kappa$ B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009, 113, 5228-5236.	0.6	70

#	ARTICLE	IF	CITATIONS
631	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2009, 114, 772-778.	0.6	145
632	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.	0.6	122
633	Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , 2009, 114, 127-127.	0.6	19
634	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009, 114, 132-132.	0.6	7
635	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009, 114, 1852-1852.	0.6	11
636	Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.. <i>Blood</i> , 2009, 114, 1871-1871.	0.6	3
637	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	0.6	18
638	Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. <i>Blood</i> , 2009, 114, 2890-2890.	0.6	6
639	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , 2009, 114, 654-654.	0.6	12
640	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. <i>Blood</i> , 2009, 114, 1722-1722.	0.6	0
641	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009, 114, 950-950.	0.6	0
642	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , 2009, 114, 2846-2846.	0.6	3
643	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009, 114, 3830-3830.	0.6	0
644	PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.. <i>Blood</i> , 2009, 114, 612-612.	0.6	0
645	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Targeted Oncology</i> , 2008, 3, 19-29.	1.7	0
646	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	1.2	94
647	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.	1.2	91
648	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 537-540.	1.2	84

#	ARTICLE	IF	CITATIONS
649	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.	1.2	55
650	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	13.9	1,787
651	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1053-1072.	1.1	79
652	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 502-507.	0.6	185
653	Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2008, 100, 373-373.	3.0	7
654	Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. <i>Clinical Cancer Research</i> , 2008, 14, 865-874.	3.2	59
655	Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.4	98
656	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	0.8	152
657	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4784-4790.	0.8	244
658	Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw. <i>Clinical Cancer Research</i> , 2008, 14, 2387-2395.	3.2	133
659	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger <i>in vivo</i> synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008, 111, 1654-1664.	0.6	193
660	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008, 112, 1329-1337.	0.6	439
661	Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. <i>Blood</i> , 2008, 112, 4343-4352.	0.6	58
662	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	0.6	153
663	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. <i>Biologics: Targets and Therapy</i> , 2008, 2, 419.	3.0	3
664	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells <i>in vitro</i> and <i>in vivo</i> . <i>Nature Precedings</i> , 2008, , .	0.1	2
665	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 129-136.	0.9	34
666	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008, 112, 1011-1011.	0.6	1

#	ARTICLE	IF	CITATIONS
667	A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.. Blood, 2008, 112, 1719-1719.	0.6	2
668	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. Blood, 2008, 112, 3662-3662.	0.6	3
669	Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM). Blood, 2008, 112, 3691-3691.	0.6	11
670	Phase I Trial of CCI-779 (Temsirrolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Blood, 2008, 112, 3696-3696.	0.6	26
671	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3700-3700.	0.6	6
672	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood, 2008, 112, 832-832.	0.6	7
673	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. Blood, 2008, 112, 92-92.	0.6	34
674	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. Blood, 2008, 112, 93-93.	0.6	16
675	The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma. , 2008, , 291-308.		0
676	The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma. , 2008, , 239-252.		0
677	Hepatic Venno-Occlusive Disease. , 2008, , 467-493.		0
678	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. Blood, 2008, 112, 2648-2648.	0.6	10
679	Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.. Blood, 2008, 112, 1690-1690.	0.6	0
680	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. Blood, 2008, 112, 1716-1716.	0.6	3
681	Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics. Blood, 2008, 112, 219-219.	0.6	31
682	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	0.6	0
683	Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clinical Advances in Hematology and Oncology, 2008, 6, 755-60.	0.3	43
684	Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs, 2007, 12, 155-163.	1.0	11

#	ARTICLE	IF	CITATIONS
685	Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 394-395.	4.3	5
686	Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 373-388.	1.5	40
687	New Drugs for Myeloma. <i>Oncologist</i> , 2007, 12, 664-689.	1.9	145
688	Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 6162-6167.	3.2	68
689	The Treatment of Relapsed and Refractory Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 317-323.	0.9	53
690	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007, 110, 1656-1663.	0.6	106
691	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	0.6	485
692	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , 2007, 109, 3177-3188.	0.6	379
693	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , 2007, 109, 2604-2606.	0.6	242
694	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 149-162.	2.3	59
695	Novel therapies in myeloma. <i>Current Opinion in Hematology</i> , 2007, 14, 609-615.	1.2	18
696	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196.	2.0	216
697	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 551-566.	1.1	12
698	Management of Relapsed and Relapsed Refractory Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1175-1215.	0.9	8
699	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1007-1034.	0.9	110
700	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 797-816.	0.7	63
701	Toward a new therapeutic backbone in myeloma. <i>Blood</i> , 2007, 109, 2672-2673.	0.6	6
702	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. <i>American Journal of Hematology</i> , 2007, 82, 831-833.	2.0	34



#	ARTICLE	IF	CITATIONS
703	Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 950-968.	1.2	83
704	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , 2007, 7, 585-598.	12.8	817
705	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.	1.2	115
706	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 138, 783-791.	1.2	102
707	Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.. <i>Blood</i> , 2007, 110, 1164-1164.	0.6	17
708	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , 2007, 110, 1165-1165.	0.6	18
709	Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. <i>Blood</i> , 2007, 110, 1170-1170.	0.6	10
710	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1179-1179.	0.6	10
711	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , 2007, 110, 1185-1185.	0.6	2
712	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.	0.6	2
713	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4493-4493.	0.6	1
714	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	0.6	2
715	Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. <i>Translational Medicine Series</i> , 2007, , 169-196.	0.0	0
716	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , 2007, 110, 1519-1519.	0.6	10
717	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2524-2524.	0.6	1
718	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007, 110, 3507-3507.	0.6	12
719	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4494-4494.	0.6	1
720	In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.. <i>Blood</i> , 2007, 110, 540-540.	0.6	1

#	ARTICLE	IF	CITATIONS
721	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , 2007, 110, 1509-1509.	0.6	1
722	Management Strategies for Relapsed Multiple Myeloma. <i>American Journal of Cancer</i> , 2006, 5, 393-409.	0.4	2
723	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , 2006, 5, 141-153.	0.4	2
724	Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2555.	3.8	134
725	Role of B-Cellâ€ Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. <i>Cancer Research</i> , 2006, 66, 6675-6682.	0.4	212
726	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. <i>Community Oncology</i> , 2006, 3, 575-582.	0.2	0
727	Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 233-235.	1.4	46
728	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 33-47.	5.0	317
729	Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Venocclusive Disease: Clinical Outcomes and Potential Mechanisms of Action. <i>Oligonucleotides</i> , 2006, 16, 105-114.	2.7	47
730	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. <i>European Journal of Cancer</i> , 2006, 42, 1564-1573.	1.3	188
731	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	0.6	398
732	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006, 108, 3458-3464.	0.6	494
733	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , 2006, 18, 598-608.	1.1	32
734	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1341-1347.	1.0	40
735	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 698-704.	1.2	4
736	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:. <i>Cancer</i> , 2006, 106, 1316-1319.	2.0	133
737	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	0.8	587
738	Recent Advances in the Treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 381-393.	0.9	15

#	ARTICLE	IF	CITATIONS
739	MLN120B, a Novel Î²B Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 5887-5894.	3.2	130
740	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1165-1173.	1.1	50
741	Can thalidomide improve outcome in patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 590-591.	4.3	3
742	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006, 108, 3460-3460.	0.6	1
743	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006, 108, 3468-3468.	0.6	2
744	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2006, 108, 3485-3485.	0.6	4
745	Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3532-3532.	0.6	6
746	A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3582-3582.	0.6	7
747	Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase I Trial.. <i>Blood</i> , 2006, 108, 405-405.	0.6	40
748	A Multicenter Phase I Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 406-406.	0.6	25
749	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3080-3080.	0.6	0
750	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3396-3396.	0.6	2
751	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2006, 108, 3591-3591.	0.6	0
752	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , 2006, 108, 3452-3452.	0.6	1
753	Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. <i>Haematologica</i> , 2006, 91, 929-34.	1.7	119
754	Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 1; discussion 8; suppl 13.	0.3	4
755	Optimizing bortezomib treatment in patients with relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 4-5; discussion 8; suppl 13.	0.3	28
756	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , 2005, 106, 1794-1800.	0.6	167

#	ARTICLE	IF	CITATIONS
757	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , 2005, 107, 1092-1100.	0.6	278
758	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005, 105, 4470-4476.	0.6	59
759	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005, 128, 192-203.	1.2	305
760	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 131, 71-73.	1.2	180
761	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257014.	1.2	73
762	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- $\beta$ inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	2.6	43
763	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , 2005, 8, 407-419.	7.7	673
764	Bortezomib in recurrent and/or refractory multiple myeloma. <i>Cancer</i> , 2005, 103, 1195-1200.	2.0	218
765	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , 2005, 104, 2141-2148.	2.0	99
766	Proteasome inhibition as an anticancer target. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 698-698.	21.5	0
767	Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6345-6350.	0.8	69
768	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 686-692.	1.9	148
769	Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. <i>Cancer Research</i> , 2005, 65, 5898-5906.	0.4	146
770	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , 2005, 1, 161-167.	1.1	33
771	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. <i>Cancer Research</i> , 2005, 65, 11712-11720.	0.4	163
772	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. <i>Cancer Research</i> , 2005, 65, 7478-7484.	0.4	97
773	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8567-8572.	3.3	571
774	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	0.6	306

#	ARTICLE	IF	CITATIONS
775	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticancer Therapy, 2005, 5, 465-476.	1.1	14
776	Plasma Cell Problems. Journal of Clinical Oncology, 2005, 23, 3138-3140.	0.8	12
777	Proteasome Inhibition in the Treatment of Cancer. Cell Cycle, 2005, 4, 289-295.	1.3	92
778	Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide. Seminars in Hematology, 2005, 42, S9-S15.	1.8	62
779	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
780	Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2005, 6, 84-88.	1.4	7
781	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. Journal of Clinical Oncology, 2005, 23, 630-639.	0.8	526
782	Novel biological therapies for the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 619-634.	0.7	46
783	Proteasome inhibitors as therapeutics. Essays in Biochemistry, 2005, 41, 205-218.	2.1	7
784	Targeting Bcl-2 as Therapy for Multiple Myeloma.. Blood, 2005, 106, 109-109.	0.6	5
785	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results.. Blood, 2005, 106, 1565-1565.	0.6	102
786	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. Blood, 2005, 106, 1571-1571.	0.6	5
787	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. Blood, 2005, 106, 247-247.	0.6	8
788	Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.. Blood, 2005, 106, 2547-2547.	0.6	27
789	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. Blood, 2005, 106, 3380-3380.	0.6	3
790	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. Blood, 2005, 106, 3398-3398.	0.6	1
791	A Phase 1 Trial of Lenalidomide (REVLIMIDÂ®) with Bortezomib (VELCADEÂ®) in Relapsed and Refractory Multiple Myeloma.. Blood, 2005, 106, 365-365.	0.6	17
792	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. Blood, 2005, 106, 4447-4447.	0.6	1

#	ARTICLE	IF	CITATIONS
793	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. Blood, 2005, 106, 1551-1551.	0.6	0
794	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	0.6	0
795	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. Blood, 2005, 106, 627-627.	0.6	0
796	Proteasome inhibition in the treatment of cancer. Cell Cycle, 2005, 4, 290-6.	1.3	42
797	New therapies for the treatment of multiple myeloma. Clinical Advances in Hematology and Oncology, 2005, 3, 345-6.	0.3	2
798	New treatments for multiple myeloma. Oncology, 2005, 19, 1781-92; discussion 1792, 1795-7.	0.4	19
799	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. Cancer Research, 2004, 64, 8746-8753.	0.4	30
800	Transforming Growth Factor $\beta$ 2 Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. Clinical Cancer Research, 2004, 10, 7540-7546.	3.2	111
801	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Research, 2004, 64, 2846-2852.	0.4	126
802	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. Cancer Research, 2004, 64, 7500-7506.	0.4	86
803	Multiple Myeloma. Hematology American Society of Hematology Education Program, 2004, 2004, 237-256.	0.9	76
804	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	1.2	74
805	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	2.6	127
806	An update of novel therapeutic approaches for multiple myeloma. Current Treatment Options in Oncology, 2004, 5, 227-238.	1.3	10
807	Proteasome inhibition in hematologic malignancies. Annals of Medicine, 2004, 36, 304-314.	1.5	59
808	Case 38-2004. New England Journal of Medicine, 2004, 351, 2637-2645.	13.9	10
809	Proteasome Inhibition. American Journal of Cancer, 2004, 3, 271-279.	0.4	0
810	Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma. Journal of Clinical Oncology, 2004, 22, 3212-3214.	0.8	68

#	ARTICLE	IF	CITATIONS
811	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. <i>Mayo Clinic Proceedings</i> , 2004, 79, 875-882.	1.4	120
812	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 635-644.	2.0	43
813	A review of the proteasome inhibitor bortezomib in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1321-1331.	0.9	43
814	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004, 103, 1787-1790.	0.6	266
815	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti- multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , 2004, 103, 3158-3166.	0.6	122
816	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Blood</i> , 2004, 103, 3474-3479.	0.6	87
817	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , 2004, 104, 2458-2466.	0.6	79
818	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	0.6	177
819	Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 1503-1503.	0.6	8
820	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. <i>Blood</i> , 2004, 104, 2403-2403.	0.6	6
821	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. <i>Blood</i> , 2004, 104, 2404-2404.	0.6	3
822	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , 2004, 104, 2405-2405.	0.6	3
823	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2004, 104, 2456-2456.	0.6	1
824	Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.. <i>Blood</i> , 2004, 104, 286-286.	0.6	7
825	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 336-336.	0.6	36
826	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004, 104, 751-751.	0.6	3
827	Hepatic Venous Occlusive Disease. , 2004, , 297-314.		0
828	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , 2004, 104, 1498-1498.	0.6	2

#	ARTICLE	IF	CITATIONS
829	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	0.6	0
830	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. Blood, 2004, 104, 3413-3413.	0.6	3
831	TGF- $\beta$ 2 Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2355-2355.	0.6	1
832	Bortezomib Targets Multiple Myeloma Endothelial Cells.. Blood, 2004, 104, 4903-4903.	0.6	0
833	Novel biologically based therapies for Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 309-312.	0.8	45
834	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 2003, 121, 592-596.	1.2	45
835	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 2003, 22, 8386-8393.	2.6	163
836	Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treatment Reviews, 2003, 29, 33-39.	3.4	79
837	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 2003, 348, 2609-2617.	13.9	2,460
838	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Current Opinion in Hematology, 2003, 10, 451-462.	1.2	128
839	The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 2003, 101, 2377-2380.	0.6	678
840	Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood, 2003, 101, 703-705.	0.6	114
841	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101, 1530-1534.	0.6	533
842	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 2003, 101, 4055-4062.	0.6	296
843	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 2003, 102, 2615-2622.	0.6	220
844	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 1578-1582.	0.6	299
845	Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. Cancer Control, 2003, 10, 361-369.	0.7	269
846	Hemostatic Complications of Hematopoietic Stem Cell Transplantation: From Hemorrhage to Microangiopathies and VOD. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 50-53.	0.5	4



#	ARTICLE	IF	CITATIONS
847	Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. <i>Oncology</i> , 2003, 17, 1063-5.	0.4	2
848	Bortezomib: a novel therapy approved for multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 596-600.	0.3	49
849	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14374-14379.	3.3	691
850	Biologic sequelae of nuclear factor- $\kappa$ B blockade in multiple myeloma: therapeutic applications. <i>Blood</i> , 2002, 99, 4079-4086.	0.6	369
851	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. <i>Blood</i> , 2002, 100, 2187-2194.	0.6	110
852	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002, 100, 3063-3067.	0.6	759
853	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , 2002, 100, 4337-4343.	0.6	328
854	Thalidomide: Emerging Role in Cancer Medicine. <i>Annual Review of Medicine</i> , 2002, 53, 629-657.	5.0	128
855	NF- $\kappa$ B as a Therapeutic Target in Multiple Myeloma. <i>Journal of Biological Chemistry</i> , 2002, 277, 16639-16647.	1.6	824
856	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , 2002, 99, 4525-4530.	0.6	640
857	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , 2002, 76, 340-341.	0.7	8
858	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002, 21, 1346-1358.	2.6	170
859	Activation of NF- $\kappa$ B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , 2002, 21, 5673-5683.	2.6	456
860	Cytokines modulate telomerase activity in a human multiple myeloma cell line. <i>Cancer Research</i> , 2002, 62, 3876-82.	0.4	131
861	Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. <i>Cancer Research</i> , 2002, 62, 4996-5000.	0.4	362
862	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2002, 62, 5019-26.	0.4	128
863	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 539-44.	1.9	101
864	Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 851-60.	1.9	104

#	ARTICLE	IF	CITATIONS
865	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	0.6	869
866	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001, 98, 428-435.	0.6	399
867	TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. <i>Blood</i> , 2001, 98, 795-804.	0.6	357
868	The role of tumor necrosis factor $\alpha$ in the pathophysiology of human multiple myeloma: therapeutic applications. <i>Oncogene</i> , 2001, 20, 4519-4527.	2.6	376
869	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	164
870	Hepatic Venocclusive Disease following Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2001, 106, 57-68.	0.7	61
871	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	130
872	Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 239-246.	1.1	7
873	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , 2000, 96, 2943-2950.	0.6	844
874	Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 1999, 17, 1175-1175.	0.8	50
875	THE PATHOLOGY, DIAGNOSIS, AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE: CURRENT STATUS AND NOVEL APPROACHES. <i>British Journal of Haematology</i> , 1999, 107, 485-493.	1.2	83
876	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409-414.		37
877	Proton Pump Inhibitors. <i>Drugs</i> , 1998, 56, 307-335.	4.9	219
878	Prevention and Treatment of Hepatic Venocclusive Disease after High-Dose Cytoreductive Therapy. <i>Leukemia and Lymphoma</i> , 1998, 31, 267-277.	0.6	23
879	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409.		1
880	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA. , 0, , 46-63.		0
881	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
882	Revised international staging system allocation in the ICARIA $\rightarrow$ MM study: Practical challenges and impact on outcome. <i>EJHaem</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
883	Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?. Exploration of Targeted Anti-tumor Therapy, 0, , 617-626.	0.5	3